Lupin is reportedly planning to acquire brands in the US markets, in order to sustain growth levels of up to 25% in the current fiscal. It has decided to introduce 20-25 products every year for the next couple of years in the US market. The entity has filed 21 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (USFDA) in 2012-13 financial year and received 14 approvals.
The company’s net profit grew by 56.70% at Rs 1260.43 crore for the year ended March 31, 2013 as compared to Rs 804.37 crore for the year ended March 31, 2012. Its total income has increased by 32.61% to Rs 7145.82 crore for the year from Rs 5388.32 crore for the previous year.
